Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 90.40M | $ 82.71M | $ 64.36M | $ 48.04M | $ 11.80M |
| Gross Profit | $ 81.52M | $ 73.35M | $ 56.70M | $ 42.88M | $ 10.79M |
| Operating Income | $ -96.78M | $ -65.54M | $ -79.04M | $ -92.29M | $ -126.74M |
| EBITDA | $ -110.33M | $ -63.83M | $ -78.03M | $ -90.15M | $ -122.71M |
| Net Income | $ -126.87M | $ -102.24M | $ -109.16M | $ -110.82M | $ -128.48M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 236.69M | $ 136.97M | $ 99.96M | $ 89.81M | $ 103.91M |
| Total Assets | $ 285.71M | $ 178.31M | $ 136.24M | $ 119.75M | $ 122.00M |
| Total Debt | $ 123.39M | $ 100.21M | $ 99.12M | $ 398.00K | $ 1.50M |
| Net Debt | $ -48.60M | $ 4.39M | $ 43.72M | $ -43.96M | $ -102.41M |
| Total Liabilities | $ 294.51M | $ 243.52M | $ 224.98M | $ 111.33M | $ 25.65M |
| Stockholders' Equity | $ -8.80M | $ -65.21M | $ -88.74M | $ 8.41M | $ 96.36M |
| Cash Flow | |||||
| Free Cash Flow | $ -97.06M | $ -76.57M | $ -87.81M | $ -85.64M | $ -107.10M |
| Operating Cash Flow | $ -96.77M | $ -76.38M | $ -87.56M | $ -84.89M | $ -105.89M |
| Investing Cash Flow | $ -20.61M | $ -953.00K | $ 1.06M | $ 4.07M | $ 93.24M |
| Financing Cash Flow | $ 194.62M | $ 116.93M | $ 97.13M | $ 72.32M | $ 16.53M |